Article ID Journal Published Year Pages File Type
3933809 European Urology Supplements 2009 5 Pages PDF
Abstract
The use of zoledronic acid has been shown to be effective in reducing SREs in patients with bone metastases from genitourinary malignancies. Clinical trials are currently ongoing to evaluate whether zoledronic acid also has a direct antitumour activity in addition to its bone-preserving activity. Although well-designed, prospective, randomised trials are needed, bone marker measurements may be used as a tool to guide treatment decisions.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Preview
Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum
Authors
, , , , ,